Synthetic Biologics Inc (SYN)

1.61
0.01 0.31
AMEX : Health Care
Prev Close 1.61
Open 1.59
Day Low/High 1.56 / 1.64
52 Wk Low/High 0.93 / 3.44
Volume 226.82K
Avg Volume 577.10K
Exchange AMEX
Shares Outstanding 91.27M
Market Cap 146.03M
EPS -0.50
P/E Ratio 2.32
Div & Yield N.A. (N.A)

Latest News

Synthetic Biologics Announces Completion Of End Of Phase 2 Meeting With FDA For SYN-010, Intended For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics Announces Completion Of End Of Phase 2 Meeting With FDA For SYN-010, Intended For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

-- FDA Provides Company with Recommendation and Guidance for Clinical Study Design for Phase 2b/3 Adaptive Trial --

Synthetic Biologics Announces Granting Of European And U.S. Composition Of Matter Patents For Ribaxamase

Synthetic Biologics Announces Granting Of European And U.S. Composition Of Matter Patents For Ribaxamase

-- First Granted Patent in Europe Directly Related to Ribaxamase, intended to Prevent C. difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms --

Synthetic Biologics Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004

Synthetic Biologics Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004

-- Ribaxamase Designed for the Prevention of C. difficile Infection, Antibiotic-Associated Diarrhea & the Emergence of Antibiotic-Resistant Organisms --

Synthetic Biologics Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

-- Phase 2 Clinical Trials Demonstrate Potential of SYN-010 to Reduce Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores without Severe Adverse Events in IBS-C Patients --

Synthetic Biologics To Host Post-DDW 2016® Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics To Host Post-DDW 2016® Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

-- Mark Pimentel, MD, FRCP(C) to Review IBS-C Patient Data from Two SYN-010 Phase 2 Clinical Trials --

Synthetic Biologics Announces Positive Topline Results From Second Phase 2a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea

Synthetic Biologics Announces Positive Topline Results From Second Phase 2a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea

-- SYN-004 Degraded IV Ceftriaxone in the Presence of a Proton Pump Inhibitor in the Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream --

Isaac J. Bright, MD, Joins Synthetic Biologics As Vice President, Corporate Development

Isaac J. Bright, MD, Joins Synthetic Biologics As Vice President, Corporate Development

-- Company Expands Strategic Partnering Efforts of Late-Stage GI Microbiome-Focused Clinical Programs --

Synthetic Biologics Appoints Deb Mathews, PharmD, As Vice President, Medical Affairs

Synthetic Biologics Appoints Deb Mathews, PharmD, As Vice President, Medical Affairs

-- Appointment Reflects Company's Late-Stage Clinical Focus and Plans to Prepare for Commercialization --

Synthetic Biologics To Report First Quarter 2016 Operational Highlights And Financial Results On May 5, 2016

Synthetic Biologics To Report First Quarter 2016 Operational Highlights And Financial Results On May 5, 2016

-- Conference Call Scheduled for Thursday, May 5, 2016 at 4:30 p.m. EDT --

Synthetic Biologics To Report 2015 Year End Results On March 10, 2016

Synthetic Biologics To Report 2015 Year End Results On March 10, 2016

-- Conference Call Scheduled for Thursday, March 10, 2016 at 4:30 p.m. EST --

Synthetic Biologics Reports Results Of Independent Third Party Evaluations Of Trimesta™ Data From Investigator-Sponsored Phase 2 Clinical Trial For Relapsing-Remitting Multiple Sclerosis

Synthetic Biologics Reports Results Of Independent Third Party Evaluations Of Trimesta™ Data From Investigator-Sponsored Phase 2 Clinical Trial For Relapsing-Remitting Multiple Sclerosis

-- Data Analysis Did Not Demonstrate Statistically Significant Differences Between Treatment and Placebo Groups --

Synthetic Biologics Reports Positive Topline Data From Second Phase 2 Clinical Trial Of SYN-010 In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics Reports Positive Topline Data From Second Phase 2 Clinical Trial Of SYN-010 In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

-- SYN-010 Demonstrated Ability to Reduce Methane Production, Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores in IBS-C Patients --

Synthetic Biologics Targeting IBS Cause, Not Just Treatment

Synthetic Biologics Targeting IBS Cause, Not Just Treatment

Shares of Synthetic Biologics are up 65% so far in 2015, due to high expectations for its 2016 gastrointestinal drugs.

2016 Will Be Big in Battle Against IBS Says Synthetic Biologics CEO

2016 Will Be Big in Battle Against IBS Says Synthetic Biologics CEO

Shares of Synthetic Biologics (SYN) are up 65% so far in 2015 due to high expectations for its gastrointestinal drugs.

Synthetic Biologics To Webcast Microbiome Clinical Program Seminar

Synthetic Biologics To Webcast Microbiome Clinical Program Seminar

-- Event to Feature Company's Two Phase 2 Clinical Programs for Treatment of Irritable Bowel Syndrome with Constipation and Prevention of C. difficile Infection --

Synthetic Biologics Announces Positive Topline Results From First Phase 2a Clinical Trial Of SYN-004, The Company's Candidate For The Prevention Of C. Difficile Infection

Synthetic Biologics Announces Positive Topline Results From First Phase 2a Clinical Trial Of SYN-004, The Company's Candidate For The Prevention Of C. Difficile Infection

-- SYN-004 Degraded IV Ceftriaxone in Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream --

Synthetic Biologics To Host Microbiome Clinical Program Seminar In New York City

Synthetic Biologics To Host Microbiome Clinical Program Seminar In New York City

-- Event to Highlight Company's Two Phase 2 Clinical Programs: Treatment of Irritable Bowel Syndrome with Constipation and Prevention of C. difficile Infection --